Medindia

X

Despite Minimal Uptake in the Crohn's Disease Drug Market, Stelara's Premium Price Will Result in Sales of Nearly $337 Million in 2018

Monday, February 22, 2010 Medical PDA News J E 4
Advertisement
Clinical Development Setback Will Delay Cimzia's Launch in Europe, According to New Findings from Decision Resources

For more information, contact:

Decision Resources, Inc.

Christopher Comfort

781-296-2597

ccomfort@dresources.com

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Certain Senesco Insiders Purchase Senesco Securiti...
S
Study of NewCardio's CardioBip Demonstrates Perfor...